


# Since Day 1, we have made strong progress towards the successful delivery of our integration

We are aspiring for substantial value creation...



... and see strong traction ahead of schedule on integration

## New operating model fully implemented

750 leaders appointed in new roles, covering 100% of levels N-1, to N-3 - ONE culture well established

## **Synergies**

On track to deliver €100 mn in '24

#### **United teams**

Recent survey showed ~82% of respondents feel 'proud' or 'engaged' about the merger

#### Implementation cost


of the €250 mn, €150 mn to date, €100 mn remains for '24/'25

Actuals/Outlook


Target

# Synergies ahead of schedule, continuing to deliver significant earnings





# Cost synergy delivery ahead of schedule with target delivery of €175+ mn




# Cost synergy implementation ahead of planning

#### Examples include



#### G&A: remove role duplications, leverage GES

Remove management roles duplication, leverage Global Enterprise Services across both organizations, optimize costs



### Integration of insurance

Merger of insurance policies, leveraging scale to negotiate better policies





#### Renegotiation of supplier contracts

All purchasing categories in scope. Supply Chain Warehousing / Logistics / Air Freight most important contributors to date

# We have taken concrete steps toward our cost synergy realization

Direct costsIndirect CostsG&A costs











~€20 mn

removed duplication
of senior roles and
optimization of spans
and layers

~€10 mn

transfer of roles to Shared Service Centres ~€10 mn

office closure in Parsippany, Amsterdam, Mumbai ~€10 mn

combination and renegotiation of insurance contracts


~€25 mn

reduction of spend from harmonized contracts (e.g., logistics, intermediates, Ingredients)


# Strong progress on revenue synergy with customers



Strong pipeline of revenue synergies...




... translates into confidence to reach targets according to plan





All BUs significantly contributing to synergy delivery
Confidence with pipeline to deliver €70 mn in 2024

# Revenue synergies delivered through cross-selling and new product concepts














# Vitamin Transformation with €200 mn profit improvement, well under way

# Cumulative profit improvement, € mn





# Optimization of site network

Vitamin B6 plan Xinghuo closed

Vitamin C plant

Jiangshan closed

Premix sites optimization

Reduction of ~1,400 FTEs

Continued review of our operations costs



# Streamlined organization

More focused and agile organization model (creation of Vitamins unit and demand vs supply organization)

Reduction of ~500 FTEs

Cost optimization program in place



# Improved cash management

Inventories reduced
by ~€100 mn through
extended production
site shut-downs, E2E
collaboration and tighter
sourcing practices

Improved cash flow by stricter expenditure controls and working capital

# Acceleration of strategic review: separating out Animal Nutrition & Health

# Strategic rationale for dsm-firmenich

Full focus on nutrition, health and beauty to better drive superior innovation-led growth

→ To enhance the commercial potential and synergies of these businesses, supporting an attractive and consistent growth outlook alongside robust margins

Separating out ANH minimizes exposure to vitamins earnings volatility and reduces capital intensity in line with long-term strategy

Does not impact the expected synergies from the merger of €350 mn

# Clear strategic benefits for ANH



Full potential of ANH best realized through different ownership structure



World leading business with most complete ingredients portfolio ideally positioned to support a growing population through more sustainable animal farming




Strengthens distinctive position as a global leader with unique, integrated combination of vitamins, premixes, performance solutions and precision nutrition

# ANH is a global leader in animal nutrition with a unique, integrated business model

Innovation leader with the most complete portfolio, largest R&D team in industry

Unique business model with customer-focused local solutions and backward integrated portfolio

Global market coverage with local presence for customer intimacy and only non-Chinese producer of full vitamin portfolio




# ANH integrates diverse businesses that offer significant future potential

## **ANH Group**


Mid-to-high single digit sales growth over midterm, supported by expected market recovery

Strong cash generation potential

## Sales, € bn



## Adj. EBITDA margin, %



# Performance Solutions & Precision Services

Broad portfolio with leading position in each category

Deep innovation and science capabilities

Exposure to trends fuelling growth in agriculture

#### Premix

Distinctive business model with backward integration

Stable, through-cycle volume growth and mixing premium

Including Ruminants Brazil business

#### Vitamins

Only non-Chinese producer of full vitamin portfolio, ensuring access to essential ingredients

Core of transformation program, with procurement and fixed production cost reduction, on plan

High single digit

Organic Sales Growth

Low-Mid single digit

20+%

Adj. EBITDA margin


10+%

# Proven track record in navigating separations and capturing value



Strong track record in successful separations

Experience in divestments and minimizing stranded costs, e.g. sale of the Materials businesses



Dedicated management team

Experienced management team including multiple leaders involved in prior separations



Staged separation plan

Focus on planning and separation blueprint in 2024. Execution of separation and new ownership structure by 2025

# ANH transaction in the course of 2025. With ANH team focused on delivering strong results

## 2024 Feb

Announcement of separation

#### 2024 H2

## **Preparation Phase 2**

- Develop operational separation blueprint
- Prepare first steps of separation execution

#### 2025 H2

## Transaction phase

 Complete sign-to-close, subject to external factors (e.g. anti-trust)









Completion

## 2024 H1

## **Preparation Phase 1**

- Establish complexity analysis, deal perimeter and 'to-be' operating models
- Assemble experienced separation team to address entanglements

## From 2025 H1

# **Execution phase**

- Start separation of ANH across all entities & functions in scope
- Assess different transaction options and start transaction process


# A focused group consisting of 3 complementary Business Units

dsm-firmenich, building a company with over €10 bn sales


# Perfumery & Beauty



Taste, Texture & Health



Health, Nutrition & Care



# Mid-term targets¹ for sales and Adj. EBITDA margin as well as cash conversion

**Organic Sales Growth** 

5-7%

Adj. EBITDA margin

22-23%

Cash-to-Sales conversion<sup>2</sup>

>10%


Dividend pay-out average 40-60% of adjusted net core earnings

Stable 1.5x-2.5x Net debt/Adj. EBITDA

- 1. For the new group dsm-firmenich
- 2. Adjusted gross operating free cash flow = Adj. EBITDA CAPEX Delta WC

# Pathway to achieve 5-7% Organic Sales Growth





## Overview

Historically, Group has been delivering sustainable organic growth of 4–5%

Delivery of **revenue synergies** will contribute **~1pp** to yearly organic sales growth in foreseeable future


Tune and acceleration growth will contribute additional ~1pp across the 3 BUs, following portfolio tuning

Together, group to reach mid-term ambition of 5-7% as a focused Category of One

dsm-firmenich •••

# Pathway to achieve 22-23% Adj. EBITDA Margin

# Pro forma Adj. EBITDA Margin Bridge, %



## Overview

Historically, Group has been delivering 19-20% Adj. EBITDA margin %

2023 margin of 18% will benefit from Vitamin transformation to gain ~1pp, mainly in HNC and to lesser extent in TTH

Delivery of **synergy** will add benefits and is expected to contribute **~2–3pp in foreseeable future**, while **tune/acceleration** across 3 BU's will deliver **another 1–2pp combined** 

Combined, all 3 business units are ready with plans to deliver Adj. EBITDA performance in line with group ambition to reach mid-term ambition of 22-23% as a focused Category of One

# Mid-term target of >10% Cash-to-sales conversion based on strict cash management while maintaining growth investment

Metric	Guidance	
Adj. EBITDA margin	22-23%	
Operating Working Capital, as a % of Sales	~28%	Target Cash-to-Sales conversion¹
CAPEX, as a % of Sales	5-6%	>10%
1. Adjusted gross operating free cash flow = Ad	j. EBITDA – CAPEX – Delta WC	

## Overview

Cash improvement as priority for dsm-firmenich

Aim to maintain Operating Working Capital ~28% based on disciplined management and normalized inventories

To invest ~6% of Sales into Capex to support long-term growth and capacity build.

Normalizing over time to 5% with strict and targeted allocation (>60% of Capex dedicated to growth investments)

Together with aspired Adj. EBITDA growth in line with mid-term targets, achievement of Adjusted Operating Free Cash Flow of >10% of Sales

# Other financial metrics



Core ROCE

Mid-term guidance

+100 bps/year

Excluding PPA,
post carve out Goodwill,
divestments



Effective tax rate

21-22%

versus 24% in 2023 tax estimate

# Capital allocation policy



# Disciplined CAPEX for organic growth

5-6% of sales to be invested into CAPEX

- 60% allocated to growth
   CAPEX
- Focus on segments with accelerate and growth promise



# Dividend

On average, mid-term payout ratio target of 40-60% of adjusted net core earnings



# M&A

Prudent and disciplined approach

Value creation is key



# Share buybacks

To be considered in absence of value-creating M&A


Mid-term capital structure

Stable 1.5x-2.5x Net debt/Adj. EBITDA

Committed to maintaining a strong investment credit rating

# Strong balance sheet enables sustained organic growth

# Group debt maturity profile, € mn



# Commentary

## Strong investment grade credit ratings

- Moody's: A3 (stable)
- S&P: A- (stable)

## Prudent financing strategy

- Strong liquidity position at 2024 Q1 (€2.1 bn)
- €1.75 bn revolving credit facilities in place
- Additional €1 bn bridge facility in place

#### Centralized financing structure in place

- Centralized financing structure with new debt raised at dsm-firmenich level
- New senior bonds are issued on a pari passu basis, applying a cross guarantee structure

Confidentin delivering our ambition

Accelerate 7 Tune 7 7

Innovation-led growth in high growth, high margin segments

>10%

5-7%

Organic Sales

22-23%

Adj. EBITDA margin

Growth

Cash-to-Sales Conversion

Dream



2 iconic companies coming together Merge

Synergy delivery according to plan, confidence in outcomes of Vitamin Transformation

Focus

Leadership position in Nutrition, Health and Beauty – backed by Science

High quality portfolio with proven ability to add value

# Fact slides

# Animal Nutrition & Health in a glance

3.2 bn

€ Revenues<sup>1</sup>

7,000
Employees worldwide

6%

Organic Sales Growth<sup>2</sup>

15%


Adj. EBITDA Margin<sup>2</sup>

55 premix 55 R&D

locations

Feeding the planet without costing the Earth

# Global Presence






ANH has a well-balanced global presence with more than 50 premix and blending facilities

# Key products

# ANH €3.2 bn 2023 Sales by Product (%)\*



#### Vitamins

Vitamins are essential for well-being and good health. They play many crucial roles in farm animals such as bone formation, disease resistance, feed efficiency, growth, fertility, and egg production. dsm-firmenich' portfolio includes all vitamins from A to Z

## Feed enzymes

Enzymes help unlock nutrient potential in feed driving feed cost optimization while at the same time improved ecological footprint of animal protein production. They allow a more efficient use of natural resources and increase animal welfare

## Formulations

A broad range of technologies transform 85% of our Nutritional ingredients into formulations, for example a fat-soluble vitamin oil into a powder form
This increases performance in terms of stability, shelf-life, heat resistance, bio-availability, physical properties

#### Carotenoids

Carotenoids are essential ingredients that are important in nutrition and reproduction. Providing sufficient carotenoids increases animal performance across species. Carotenoids also ensure consistent pigmentation of eggs and fish such as salmon

#### **Premix Solutions**

We offer our clients regional and segment-specific premix solutions: a broad network of 55 premix facilities allows us to offer tailor-made, localized customer-driven solutions

## **Gut Health - Eubiotics**

Play an essential role in supporting animal performance and welfare by supporting gut health. Good gut health is a prerequisite for efficient and environmentally sound farm animals. The correct balance of microflora in the intestinal tract is essential for optimal gut performance

# Mycotoxin Risk Management

Mycotoxins are secondary metabolites of molds, contaminating a wide range of crop plants and fruits. Such contaminated crops are toxic to humans and animals.

#### Minerals

Minerals are needed in very small amounts in feed. Animals need certain minerals for instance to build strong bones and turn the feed into energy. As with vitamins, a healthy balanced diet should provide all the minerals needed to work properly

#### Precision


Sustainability service that combines the most advanced environmental foot printing calculation tool with expert sustainability, animal production and nutritional knowledge to create tailor-made solutions that enhance the environmental sustainability and profitability of animal farming.

<sup>\*</sup> Including ingredients sold via premix

# End-Markets – strong basis across all species

Split ANH 2023 sales by specie





# Productivity & sustainability drive demand for feed solutions

# demand for feed solutions Key trends Offering new opportunities ... ... for which dsm-firmenich is uniquely positioned Professionalization of farming and ensuring farmers can earn a living Digital Precision farming, labeling Sustell®, Verax, FarmTell®

Helping tackle antimicrobial resistance






















Radical more sustainable farming

Veramaris, Balancius, Midori., Bovaer, Mycotoxin Management Solutions

Probiotics, Prebiotics, Enzymes and Eubiotics for gut health

Strong position in LATAM and Asia; large potential for higher inclusion rates of nutritional ingredients to improve 'feed to meat' yields

We make this possible; with a unique portfolio and our science-based innovation program



This presentation contains forward-looking statements with respect to dsm-firmenich's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of dsm-firmenich and information currently available to the company. dsm-firmenich cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. Also, for a variety of reasons including many factors outside the control of dsm-firmenich, there can be no guarantee that the proposed separation of ANH will be decided and completed within the expected time frame or at all. Nor can there be any guarantee that dsm-firmenich or a separate ANH business will be able to realize any of the potential strategic benefits, synergies or opportunities or any guarantee that shareholders will achieve any particular level of return in relation thereto. dsm-firmenich has no obligation to update the statements contained in this presentation, unless required by law. The English language version of this press release prevails over other language versions.

A more comprehensive discussion of the risk factors affecting dsm-firmenich's business can be found on the company's corporate website, www.dsm-firmenich.com as well as in the companies Integrated Annual Report 2023.

This presentation includes information that is presented on a pro forma basis ('pro forma figures') as well as other alternative performance measures (APMs), and information that is presented in accordance with IFRS as issued by the International Accounting Standard Board ('IFRS figures').

# We bring progress to life